文献速递骨软组织肉瘤与黑色素瘤

荷兰皮肤黑色素瘤分期别发病与生存趋势(2003-2018)

Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study.
PubMed 文献 · Eur J Cancer · 2021-07-10

基于荷兰全国癌症登记处60267例浸润性原发性皮肤黑色素瘤患者,分析2003-2018年分期别发病率和生存趋势,以及前哨淋巴结活检(SLNB)和新型药物的使用变化。结果显示男性发病率从10.9升至23.9,女性从15.6升至27.3,SLNB比例从23%升至64%,五年相对生存率男性从81%升至92%、女性从88%升至96%。

要点

  • 男性发病率从10.9升至23.9,女性从15.6升至27.3,主要反映I期和III期发病率增加。
  • SLNB比例从23%升至64%,阳性率从2%升至11%。
  • 五年相对生存率男性从81%升至92%,女性从88%升至96%,反映II、III、IV期生存改善。

核心结论

  • 观察到I期和III期患者发病率增加,II、III、IV期患者生存改善。
  • 这些趋势可部分由SLNB和新型药物的引入解释。

研究设计与样本

  • 基于荷兰全国癌症登记处的全国性 population-based 研究,纳入60267例浸润性原发性皮肤黑色素瘤患者。
  • 分析2003-2018年年龄标准化发病率、SLNB比例、接受新型药物(针对原发诊断)比例及1年和5年相对生存率。

主要发现

  • 2003-2018年男性发病率从10.9升至23.9,女性从15.6升至27.3,增加反映I期和III期发病率上升。
  • SLNB比例从23%升至64%,阳性结局比例从2%升至11%。
  • IV期患者自2013年起从化疗转向新型药物。
  • 五年相对生存率男性从81%升至92%,女性从88%升至96%,增加反映II、III、IV期五年相对生存率提高。

临床怎么用

  • SLNB使用增加和新型药物引入可能部分解释II、III、IV期生存改善,提示临床应关注分期别诊疗策略的演变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine stage-specific trends in the incidence and survival of cutaneous melanoma in the Netherlands between 2003 and 2018, as well as the uptake of the sentinel lymph node biopsy (SLNB) and novel drugs during that period. METHODS: Data were obtained from the nationwide population-based Netherlands Cancer Registry for all patients diagnosed with invasive primary cutaneous melanoma (n = 60,267). We presented age-standardized incidence rates, the proportion of patients with an SLNB, the proportion of patients who received a novel drug (for their primary diagnosis) and one- and five-year relative survival rates. RESULTS: Between 2003 and 2018, the incidence rate increased from 10.9 to 23.9 for men and from 15.6 to 27.3 for women. This increase reflected the increasing incidence rate of patients with stage I and III. The proportion of patients with an SLNB increased from 23% to 64%. A reasonable increase was observed in the proportion of patients with a positive outcome (from 2% to 11%). For patients with stage IV, there was a shift from chemotherapy towards novel drugs as from 2013. The five-year relative survival rate increased from 81% to 92% for men and from 88% to 96% for women. This increase reflected the increasing five-year relative survival rate of patients with stage II, III, and IV. CONCLUSION: We observed an increase in incidence for patients with stage I and III and an improvement in survival for patients with stage II, III and IV. These trends can be partly explained by the introduction of the SLNB and the novel drugs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Leeneman B, Schreuder K, Uyl-de Groot CA, et al. Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. Eur J Cancer. 2021. PMID: 34256280. doi:10.1016/j.ejca.2021.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。